BRPI0811526A2 - uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa - Google Patents

uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa

Info

Publication number
BRPI0811526A2
BRPI0811526A2 BRPI0811526A BRPI0811526A BRPI0811526A2 BR PI0811526 A2 BRPI0811526 A2 BR PI0811526A2 BR PI0811526 A BRPI0811526 A BR PI0811526A BR PI0811526 A BRPI0811526 A BR PI0811526A BR PI0811526 A2 BRPI0811526 A2 BR PI0811526A2
Authority
BR
Brazil
Prior art keywords
isolated
antibody
humanized
chimeric
binds
Prior art date
Application number
BRPI0811526A
Other languages
English (en)
Portuguese (pt)
Inventor
Wheeler Alistair
White Barbara
L Spitalny George
Koike Masamichi
Original Assignee
Biowa Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biowa Inc, Medimmune Llc filed Critical Biowa Inc
Publication of BRPI0811526A2 publication Critical patent/BRPI0811526A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0811526A 2007-05-14 2008-05-14 uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa BRPI0811526A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92442207P 2007-05-14 2007-05-14
US92483207P 2007-06-01 2007-06-01
US93500507P 2007-07-20 2007-07-20
US6461208P 2008-03-14 2008-03-14
PCT/US2008/006156 WO2008143878A1 (en) 2007-05-14 2008-05-14 Methods of reducing eosinophil levels

Publications (1)

Publication Number Publication Date
BRPI0811526A2 true BRPI0811526A2 (pt) 2017-05-16

Family

ID=40122040

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811526A BRPI0811526A2 (pt) 2007-05-14 2008-05-14 uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa

Country Status (24)

Country Link
US (3) US20100291073A1 (enExample)
EP (2) EP3072525B1 (enExample)
JP (7) JP2010527356A (enExample)
KR (3) KR101827179B1 (enExample)
CN (2) CN101848732B (enExample)
AU (3) AU2008255027B2 (enExample)
BR (1) BRPI0811526A2 (enExample)
CA (2) CA2986531C (enExample)
CY (2) CY1117594T1 (enExample)
DK (2) DK2068927T3 (enExample)
ES (2) ES2666165T3 (enExample)
HR (2) HRP20160058T1 (enExample)
HU (2) HUE036885T2 (enExample)
IL (2) IL202102A (enExample)
LT (1) LT3072525T (enExample)
MX (3) MX2009012341A (enExample)
NO (1) NO3072525T3 (enExample)
NZ (2) NZ741494A (enExample)
PL (2) PL3072525T3 (enExample)
PT (2) PT3072525T (enExample)
RU (2) RU2519227C2 (enExample)
SG (2) SG10202000728UA (enExample)
SI (2) SI3072525T1 (enExample)
WO (1) WO2008143878A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104039352A (zh) * 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
RS67279B1 (sr) * 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT201900311T1 (it) * 2013-08-12 2019-07-11 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
BR112016002462A8 (pt) * 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
LT3060229T (lt) * 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP6768639B2 (ja) * 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
AU2016272399B2 (en) * 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CA3087063A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinophilic disorders
EP3841201A1 (en) 2018-08-24 2021-06-30 Yeda Research and Development Co. Ltd Methods of modulating m2 macrophage polarization and use of same in therapy
TW202110479A (zh) 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
KR102697770B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인간 IL-5Rα에 결합하는 항체 및 이의 용도
JP2023553641A (ja) 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
WO2023049803A1 (en) * 2021-09-22 2023-03-30 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers
CN115671140B (zh) * 2022-10-31 2024-03-22 华中科技大学同济医学院附属同济医院 丙酸痤疮杆菌在制备治疗鼻息肉的药品中的应用
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633187A (en) 1898-12-20 1899-09-19 Alba L Holmes Meter-box.
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6465616B1 (en) 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7033840B1 (en) * 1999-11-09 2006-04-25 Sri International Reaction calorimeter and differential scanning calorimeter for the high-throughput synthesis, screening and characterization of combinatorial libraries
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20060147523A1 (en) * 2002-10-16 2006-07-06 Alan Fergusson Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
AU2004279740A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20050095602A1 (en) * 2003-11-04 2005-05-05 West Jason A. Microfluidic integrated microarrays for biological detection
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006071280A1 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK1945665T3 (da) 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos

Also Published As

Publication number Publication date
CY1117594T1 (el) 2017-04-26
AU2016273830A1 (en) 2017-01-05
JP2022023157A (ja) 2022-02-07
HUE026728T2 (en) 2016-06-28
AU2016273830B2 (en) 2019-01-17
AU2008255027A1 (en) 2008-11-27
LT3072525T (lt) 2018-05-10
SI2068927T1 (sl) 2016-05-31
JP2016034940A (ja) 2016-03-17
RU2014105496A (ru) 2015-08-20
SI3072525T1 (en) 2018-06-29
EP3072525A1 (en) 2016-09-28
HUE036885T2 (hu) 2018-08-28
RU2618455C2 (ru) 2017-05-03
CY1120417T1 (el) 2019-07-10
CN101848732A (zh) 2010-09-29
IL240179A0 (en) 2015-09-24
CA2986531C (en) 2020-02-25
CA2685222A1 (en) 2008-11-27
NO3072525T3 (enExample) 2018-06-30
KR20150107890A (ko) 2015-09-23
ES2666165T3 (es) 2018-05-03
DK2068927T3 (da) 2016-01-18
AU2013273774A1 (en) 2014-01-16
KR20160010891A (ko) 2016-01-28
PL3072525T3 (pl) 2018-07-31
DK3072525T3 (en) 2018-04-30
HRP20180611T1 (hr) 2018-06-01
PT2068927E (pt) 2016-02-10
IL240179B (en) 2018-12-31
KR101827179B1 (ko) 2018-02-07
KR20100022468A (ko) 2010-03-02
HK1132658A1 (zh) 2010-03-05
MX388895B (es) 2025-03-20
CA2685222C (en) 2017-12-19
US20140004109A1 (en) 2014-01-02
NZ741494A (en) 2022-11-25
EP2068927A4 (en) 2012-06-20
NZ599278A (en) 2013-12-20
US20100291073A1 (en) 2010-11-18
US9815895B2 (en) 2017-11-14
MX2015011174A (es) 2016-06-14
US20120148575A1 (en) 2012-06-14
WO2008143878A1 (en) 2008-11-27
JP2019194242A (ja) 2019-11-07
EP3072525B1 (en) 2018-01-31
IL202102A (en) 2015-08-31
AU2008255027B2 (en) 2013-10-03
JP2010527356A (ja) 2010-08-12
ES2558689T3 (es) 2016-02-08
CN101848732B (zh) 2013-06-05
EP2068927A1 (en) 2009-06-17
HK1187542A1 (en) 2014-04-11
RU2519227C2 (ru) 2014-06-10
PT3072525T (pt) 2018-04-20
MX2020011303A (es) 2021-12-17
KR101588061B1 (ko) 2016-01-25
JP2018021017A (ja) 2018-02-08
SG10202000728UA (en) 2020-03-30
PL2068927T3 (pl) 2016-06-30
HRP20160058T1 (hr) 2016-04-22
MX376656B (es) 2025-03-07
JP2023159349A (ja) 2023-10-31
AU2013273774B2 (en) 2016-09-15
SG10201503254TA (en) 2015-06-29
US8501176B2 (en) 2013-08-06
JP2025087854A (ja) 2025-06-10
MX2009012341A (es) 2010-02-17
CN103223167B (zh) 2015-06-17
HK1148220A1 (en) 2011-09-02
CN103223167A (zh) 2013-07-31
IL202102A0 (en) 2010-06-16
RU2009146125A (ru) 2011-06-20
EP2068927B1 (en) 2015-10-21
CA2986531A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
EP4159860A4 (en) HUMANIZED ANTI-IGF-1 RECEPTOR ANTIBODY
BRPI0912035A2 (pt) anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
IL202102A0 (en) Use of a monoclonal, chimeric humanized or human antibody that binds il-5r in the manufacture of a medicament for reducing eosinophil levels
NO20190202A1 (no) Anvendelse av anti-CGRP antagonist antistoff
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
EP4032907A4 (en) Bcma-targeted antibody and chimeric antigen receptor
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
BRPI1005984A2 (pt) anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
HUE037642T2 (hu) Humán cd134 (ox40) humán monoklonális antitest és eljárások annak elõállítására és alkalmazására
ATE517183T1 (de) Monoklonaler antikörper gegen cd20
CL2013000390A1 (es) Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.
IL243375B (en) A human monoclonal antibody that binds to mesothelin
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
BRPI0908508A2 (pt) anticorpo monoclonal nkg2a anti-humano humanizado
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
HUE048404T2 (hu) Claudin-18 elleni monoklonális antitestek rák kezelésére
NZ602294A (en) Monoclonal antibodies against c-met
CR9186A (es) Composiciones y procedimientos referidos a anticuerpos contra el receptor de igf-1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOWA, INC. (US) , ASTRAZENECA AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25G Requested change of headquarter approved

Owner name: BIOWA, INC. (US) ; ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE) ; KYOWA HAKKO KIRIN CO., LTD.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ASTRAZENECA AB (SE) ; KYOWA KIRIN CO., LTD. (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: ASTRAZENECA AB (SE) ; KYOWA KIRIN CO., LTD. (JP)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]